{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03679455",
      "OrgStudyIdInfo": {
        "OrgStudyId": "ML39235"
      },
      "Organization": {
        "OrgFullName": "Polish Myeloma Consortium",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1",
      "OfficialTitle": "A Multicenter, Single-arm, Phase II Study to Evaluate a Safety and Efficacy of Obinutuzumab Induction Followed by 2 Years of Maintenance in Patients With Relapsed/Refractory Waldenström Macroglobulinemia.",
      "Acronym": "OBI-1"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2018",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 21, 2018",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 2019",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 4, 2018",
      "StudyFirstSubmitQCDate": "September 19, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 20, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 9, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 13, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Polish Myeloma Consortium",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Roche Pharma AG",
            "CollaboratorClass": "INDUSTRY"
          },
          {
            "CollaboratorName": "Bioscience, S.A.",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a multi-center, single-arm, open label, non-randomized, phase II study designed to investigate the efficacy, safety and tolerability of obinutuzumab given as monotherapy in patients with relapsed/refractory Waldenström Macroglobulinemia (R/R MW).",
      "DetailedDescription": "Study to investigate the efficacy, safety and tolerability of obinutuzumab administered as monotherapy in patients with relapsed/refractory Waldenström Macroglobulinemia (R/R WM)"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Waldenstrom Macroglobulinemia"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignInterventionModelDescription": "multi-center, single-arm, open label, non-randomized",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Treatment arm",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Obinutuzumab (RO5072759) 25 MG/ML; Obinutuzumab will be administered by iv. infusion as an absolute (flat) dose of 1000 mg.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Obinutuzumab 25 MG/ML"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Obinutuzumab 25 MG/ML",
            "InterventionDescription": "Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment arm"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Gazyvaro"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Best Overall Response (BOR)",
            "PrimaryOutcomeDescription": "BOR is the best response recorded from the start of the treatment until disease progression: response assessments recorded as CR, VGPR, PR, MR, SD, PD. As a responder is considered patient with at least MR (CR, VGPR, PR, MR). BOR will be presented as rates with corresponding exact 95% CI.",
            "PrimaryOutcomeTimeFrame": "Up to 3,5 years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Progression Free Survival (PFS)",
            "SecondaryOutcomeDescription": "PFS will be calculated as time from fist treatment dose until progression or death of any cause. The PFS will be defined as well-documented and verifiable data. The Kaplan-Meier curve will be provided. The median time to PFS along with associated 95% confidence interval will be provided as well.",
            "SecondaryOutcomeTimeFrame": "Up to 3,5 years"
          },
          {
            "SecondaryOutcomeMeasure": "Overall Survival (OS)",
            "SecondaryOutcomeDescription": "OS is defined as time from first study treatment dose to death due to any cause. Survival distributions will be estimated using the Kaplan-Meier method. Each subject will be followed for 1 year after the treatment period.",
            "SecondaryOutcomeTimeFrame": "from first study treatment dose till 1 year after the treatment period"
          },
          {
            "SecondaryOutcomeMeasure": "Overall Response Rate (ORR)",
            "SecondaryOutcomeDescription": "ORR as a secondary endpoint will be assessed after completion of induction phase and after maintenance phase. Responders include subjects with at least MR (CR, VGPR, PR, MR). Non-responders include subjects with Stable Disease (SD) and Progressive Disease (PD). Subjects with unknown or missing responses will be considered as non-responders.",
            "SecondaryOutcomeTimeFrame": "after 6 Cycles of obinutuzumab treatment (after induction phase); each cycle is 21 days in Induction Phase;"
          },
          {
            "SecondaryOutcomeMeasure": "Overall Response Rate (ORR)",
            "SecondaryOutcomeDescription": "ORR as a secondary endpoint will be assessed after completion of induction phase and after maintenance phase. Responders include subjects with at least MR (CR, VGPR, PR, MR). Non-responders include subjects with Stable Disease (SD) and Progressive Disease (PD). Subjects with unknown or missing responses will be considered as non-responders.",
            "SecondaryOutcomeTimeFrame": "after all 12 Cycles of treatment in Maintenance Phase (at first visit in follow-up phase FU2M) or after the last dose, if not after 12 Cycles of obinutuzumab (each cycle is 8 weeks in Maintenance Phase;"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSigned written informed consent prior to beginning study-related procedures.\nMale and female subjects aged ≥ 18 years.\nAble to comply with the study protocol, in the investigator's judgment.\nConfirmed clinicopathological diagnosis of WM with detectable CD20 positive of the tumor cells\nMeasurable disease defined as serum monoclonal IgM >0.5 g/dL\n\nActive disease and indication for treatment based on the Seventh IWWM recommendations (Dimopoulos et al., 2014) defined by presence of at least any one of the following conditions:\n\nRecurrent fever, night sweats, weight loss, fatigue\nHyperviscosity\nLymphadenopathy which is either symptomatic or bulky (≥5 cm in maximum diameter)\nSymptomatic hepatomegaly and/or splenomegaly\nSymptomatic organomegaly and/or organ or tissue infiltration\nPeripheral neuropathy due to WM\nSymptomatic cryoglobulinemia\nCold agglutinin anemia\nImmune hemolytic anemia and/or thrombocytopenia\nNephropathy related to WM\nAmyloidosis related to WM\nHemoglobin ≤10 g/dL\nPlatelet count <100 × 109/L\nSubjects must have received prior therapies for their WM and have relapsed or refractory WM requiring therapy. Any number of prior therapies is acceptable. Relapsed WM: defined as a subject who has received at least one prior WM therapy and previously achieved a complete or partial remission/response lasting at least 6 months Refractory WM: is defined as progression on treatment; disease progression < 6 months of the last anti-WM therapy\n\nSubjects must have adequate organ and marrow function as defined below:\n\nAbsolute neutrophil count ≥ 1.5 x 109/l (unless decreased due to WM involvement of the bone marrow)\nPlatelets ≥ 75 x 109/l (unless decreased due to WM involvement of the bone marrow)\nHemoglobin ≥ 9 g/dL\nTotal bilirubin ≤ 1.5 x ULN or < 2 x ULN if attributable to hepatic infiltration by neoplastic disease\nAST and ALT < 2.5 x ULN\nCalculated creatinine clearance by Cockcroft-Gault formula >40 mL/min\nINR ≤ 1.5\nEastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.\nFertile men or women of childbearing potential, unless ≥ 2 years after the onset of menopause (for women), must be willing to use a highly effective contraceptive method (Pearl Index < 1) such as oral contraceptives, intrauterine device, sexual abstinence or barrier method of contraception in conjunction with spermicidal jelly, during study treatment and for 18 months after end of obinutuzumab treatment.\n\nExclusion Criteria:\n\nLactating women, women with a positive pregnancy test at Visit 1 or women (of childbearing potential) as well as men with partners of childbearing potential, who are not willing to use adequate contraception from study start through 18 months after end of obinutuzumab treatment.\nKnown involvement of the central nervous system by WM.\nVaccination with a live vaccine a minimum of 28 days prior to study enrolment (vaccination day considered as Day 0).\nHistory of stroke or intracranial hemorrhage within 12 months prior to study enrollment.\nCurrently active, clinically significant cardiovascular disease.\nAny active systemic infection. Caution should be exercised when considering the use of obinutuzumab in patients with a history of recurring or chronic infections.\nPositive for hepatitis C antibody at screening.\nPositive test result for chronic hepatitis B virus (HBV) infection (defined as a positive HBsAg serology). Patients with occult or prior HBV infection (defined as negative hepatitis B surface antigen [HBsAg] and positive total hepatitis B core antibody [HBcAb]) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing during treatment and follow-up until 12 months after the last dose of obinutuzumab.\nKnown HIV infection at screening.\nAny serious illness, medical condition, organ system dysfunction or abnormality in clinical laboratory test that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.\nConcurrent use of other anti-cancer agents or treatments.\nPrior use of any investigational monoclonal antibody therapy within 6 months of study start.\nHistory of severe allergic or anaphylactic reactions to monoclonal antibody therapy, known hypersensitivity to any of the study drugs or sensitivity to murine products.\nTreatment with any known non-marketed drug substance or experimental therapy within 5 terminal half-lives or 4 Weeks prior to first study treatment dose, whichever is longer, or participation in any other interventional clinical study.\nPrior use of radiation therapy within 4 weeks of enrollment.\nHistory of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer.\nHistory of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Tomasz Wróbel, MD, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+48 501 419 272",
            "CentralContactEMail": "wrobeltw@gmail.com"
          },
          {
            "CentralContactName": "Dominik Dytfeld, MD, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+48 602 464 708",
            "CentralContactEMail": "dytfeld@me.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Tomasz Wróbel, MD.PhD",
            "OverallOfficialAffiliation": "USK Wrocław",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Uniwersytecki Szpital kliniczy im. Jana Mikulicza-Radeckiego we Wrocławiu; Klinika Hematologii, Nowotworów Krwi Transplantacji Szpiku",
            "LocationStatus": "Recruiting",
            "LocationCity": "Wrocław",
            "LocationState": "Dolnośląskie",
            "LocationZip": "50-367",
            "LocationCountry": "Poland",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Tomasz Wróbel, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+48 501 419 272",
                  "LocationContactEMail": "wrobeltw@gmail.com"
                },
                {
                  "LocationContactName": "Agnieszka Szeremet, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+48 71 784 22 77",
                  "LocationContactEMail": "agnieszka.szeremet@wp.pl"
                },
                {
                  "LocationContactName": "Tomasz Wróbel, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                },
                {
                  "LocationContactName": "Agnieszka Szeremet, MD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Elżbieta Kalicińska, MD",
                  "LocationContactRole": "Sub-Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu; Oddział Hematologii i Transplantacji Szpiku",
            "LocationStatus": "Recruiting",
            "LocationCity": "Poznań",
            "LocationState": "Wielkopolskie",
            "LocationZip": "60-569",
            "LocationCountry": "Poland",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Dominik Dytfeld, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+48 602464708",
                  "LocationContactEMail": "dytfeld@me.com"
                },
                {
                  "LocationContactName": "Elżbieta Gwazdacz-Magiera",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+48 535818919",
                  "LocationContactEMail": "egm1@tlen.pl"
                },
                {
                  "LocationContactName": "Dominik Dytfeld, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                },
                {
                  "LocationContactName": "Adam Nowicki, MD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Tomasz Szczepanik, MD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Bartosz Małecki, MD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Magdalena Matuszak, MD",
                  "LocationContactRole": "Sub-Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008258",
            "ConditionMeshTerm": "Waldenstrom Macroglobulinemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000054219",
            "ConditionAncestorTerm": "Neoplasms, Plasma Cell"
          },
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000020141",
            "ConditionAncestorTerm": "Hemostatic Disorders"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000010265",
            "ConditionAncestorTerm": "Paraproteinemias"
          },
          {
            "ConditionAncestorId": "D000001796",
            "ConditionAncestorTerm": "Blood Protein Disorders"
          },
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          },
          {
            "ConditionAncestorId": "D000006474",
            "ConditionAncestorTerm": "Hemorrhagic Disorders"
          },
          {
            "ConditionAncestorId": "D000008232",
            "ConditionAncestorTerm": "Lymphoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000008206",
            "ConditionAncestorTerm": "Lymphatic Diseases"
          },
          {
            "ConditionAncestorId": "D000007160",
            "ConditionAncestorTerm": "Immunoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10403",
            "ConditionBrowseLeafName": "Waldenstrom Macroglobulinemia",
            "ConditionBrowseLeafAsFound": "Waldenstrom Macroglobulinemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M26741",
            "ConditionBrowseLeafName": "Neoplasms, Plasma Cell",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21130",
            "ConditionBrowseLeafName": "Hemostatic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4211",
            "ConditionBrowseLeafName": "Blood Coagulation Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12330",
            "ConditionBrowseLeafName": "Paraproteinemias",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4229",
            "ConditionBrowseLeafName": "Blood Protein Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8712",
            "ConditionBrowseLeafName": "Hemorrhagic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10377",
            "ConditionBrowseLeafName": "Lymphoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10355",
            "ConditionBrowseLeafName": "Lymphatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9358",
            "ConditionBrowseLeafName": "Immunoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T5887",
            "ConditionBrowseLeafName": "Waldenstrom Macroglobulinemia",
            "ConditionBrowseLeafAsFound": "Waldenstrom Macroglobulinemia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "C000543332",
            "InterventionMeshTerm": "Obinutuzumab"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000074322",
            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M3377",
            "InterventionBrowseLeafName": "Antibodies",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9336",
            "InterventionBrowseLeafName": "Immunoglobulins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3382",
            "InterventionBrowseLeafName": "Antibodies, Monoclonal",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M288910",
            "InterventionBrowseLeafName": "Obinutuzumab",
            "InterventionBrowseLeafAsFound": "Depth",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M1346",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          }
        ]
      }
    }
  }
}